Omeros is developing a deep pipeline of product candidates to treat inflammation, coagulopathies and central nervous system disorders. We currently have nine programs focused on inflammation, coagulopathies, multiple CNS programs and G protein-coupled receptors in development, all targeting large markets.
Our most clinically advanced product candidates in the area of inflammation are derived from our proprietary PharmacoSurgery platform, designed to improve the clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. In addition to our PharmacoSurgery platform, we have one other program in preclinical development to treat inflammatory disorders.
Our clinical program for the treatment and prevention of addiction and our preclinical programs targeting other CNS disorders and coagulopathies broaden our pipeline and help create multiple opportunities for commercial success.
For each of our product candidates and programs, we have retained all manufacturing, marketing and distribution rights.